FY2024 Earnings Forecast for Valneva Issued By HC Wainwright

Valneva SE (NASDAQ:VALN) – Analysts at HC Wainwright reduced their FY2024 earnings per share (EPS) estimates for shares of Valneva in a report released on Thursday, January 23rd. HC Wainwright analyst E. White now anticipates that the company will post earnings per share of $0.13 for the year, down from their previous forecast of $0.15. HC Wainwright currently has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for Valneva’s current full-year earnings is $0.15 per share. HC Wainwright also issued estimates for Valneva’s FY2025 earnings at ($1.29) EPS and FY2026 earnings at ($1.17) EPS.

Valneva Trading Up 2.1 %

Shares of Valneva stock opened at $4.95 on Monday. The company has a 50 day simple moving average of $4.30 and a two-hundred day simple moving average of $5.72. The firm has a market cap of $402.24 million, a PE ratio of -38.08 and a beta of 1.93. Valneva has a 1 year low of $3.62 and a 1 year high of $9.50. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Valneva stock. AlphaCentric Advisors LLC lifted its position in Valneva SE (NASDAQ:VALN) by 33.7% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 118,000 shares of the company’s stock after purchasing an additional 29,748 shares during the quarter. AlphaCentric Advisors LLC owned 0.15% of Valneva worth $717,000 at the end of the most recent quarter. 11.39% of the stock is owned by institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.